Cambridge Cancer Genomics Company
Cambridge Cancer Genomics is using blood tests to guide smarter cancer therapy. Currently, cancer patients have to wait up to 6 months to know whether their chemotherapy is working. In the interim, patients suffer the side effects of such treatments. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. In addition, we can identify relapse an average of 7 months earlier than standard practice. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment.